2010年12月23日 · A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the...

2012年4月5日 · A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the...

2010年8月31日 · The multinational EINSTEIN-DVT study was designed to investigate a new single-drug approach with rivaroxaban in comparison to standard therapy in a randomised, open-label, non-inferiority study. The trial involved more than 3,400 patients with acute symptomatic DVT, but without any symptoms of pulmonary embolism, across 253 sites in 32 ...

We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous...

2010年1月1日 · In the extension study (EINSTEIN–Extension), the primary outcome occurred in 1.3% of the rivaroxaban group versus 7.1% of the placebo group (p < 0.001). The primary safety outcome, major and clinically relevant nonmajor bleeding, occurred in 8.1% of the rivaroxaban group versus 8.1% of the enoxaparin/vitamin K antagonist group (p = 0.71).

2010年11月19日 · Current guidelines advise indefinite therapy in a substantial proportion of DVT patients. The Einstein-DVT study was designed to compare rivaroxaban, a direct oral factor Xa inhibitor, to enoxaparin followed by oral vitamin K antagonist (VKA) treatment in patients with acute DVT for either 3, 6, or 12 months.

2018年9月12日 · In the EINSTEIN DVT and EINSTEIN PE trials, rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily thereafter) was shown to be an effective and safe alternative to standard anticoagulation for the treatment of deep vein thrombosis and pulmonary embolism in a broad range of adult patients.

The EINSTEIN clinical trial programme comprises four randomised Phase 3 studies of rivaroxaban for the treatment of VTE and the long-term prevention of recurrent VTE. It is the only clinical programme that has investigated a non-vitamin K antagonist oral anticoagulant for the treatment of acute DVT and treatment for acute PE in separate trials.

2012年11月16日 · The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose regimen of rivaroxaban was non-inferior to standard therapy of subcutaneous enoxaparin followed by vitamin K antagonist (VKA) for the treatment of symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), with similar occurrence of clinically relevant bleeding (The ...

2013年9月20日 · Methods: A prespecified pooled analysis of the EINSTEIN-DVT and EINSTEIN-PE studies compared the efficacy and safety of rivaroxaban (15 mg twice-daily for 21 days, followed by 20 mg once-daily) with standard-therapy (enoxaparin 1.0 mg/kg twice-daily and warfarin or acenocoumarol).